Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review

Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review

Abstract The coronavirus disease 2019 (COVID‐19) pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three quarters of patients with COVID‐19 admitted to the intensive care unit, and bot...

Full description

Bibliographic Details
Main Authors: Christopher D. Barrett, Hunter B. Moore, Ernest E. Moore, Robert C. McIntyre, Peter K. Moore, John Burke, Fei Hua, Joshua Apgar, Daniel S. Talmor, Angela Sauaia, Deborah R. Liptzin, Livia A. Veress, Michael B. Yaffe
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
acute respiratory distress syndrome
COVID‐19
fibrinolysis
pulmonary failure
tissue plasminogen activator
Online Access:https://doi.org/10.1002/rth2.12357

Internet

https://doi.org/10.1002/rth2.12357

Similar Items